AdaptHealth Reports Q4 & FY2025 Net Loss and Adjusted EBITDA Decline, Issues Positive 2026 Guidance

summarizeSummary

AdaptHealth Corp. reported a net loss and decreased Adjusted EBITDA for Q4 and full-year 2025, primarily due to a goodwill impairment, but provided 2026 guidance projecting revenue and Adjusted EBITDA growth.

check_boxKey Events

• Q4 and Full-Year 2025 Financial Results

  For Q4 2025, net revenue decreased 1.2% to $846.3 million, and the company reported a net loss of $102.8 million compared to net income of $50.3 million in Q4 2024. Full-year 2025 net revenue decreased 0.5% to $3,244.9 million, resulting in a net loss of $70.8 million compared to net income of $90.4 million in 2024. Adjusted EBITDA declined 18.7% in Q4 and 10.5% for the full year.

• Significant Goodwill Impairment Charge

  The full-year and fourth quarter 2025 net losses included a non-cash goodwill impairment charge of $128.0 million, primarily related to the Diabetes Health reporting unit.

• Debt Reduction and Cash Flow

  The company reduced debt by $25 million in Q4 2025, contributing to a total debt reduction of $250 million for the full year. Full-year 2025 cash flow from operations increased to $601.8 million from $541.8 million in 2024, while free cash flow decreased slightly to $219.4 million.

• 2026 Financial Guidance Provided

  AdaptHealth issued guidance for fiscal year 2026, projecting net revenue between $3.44 billion and $3.51 billion, Adjusted EBITDA between $680 million and $730 million, and free cash flow between $175 million and $225 million. This guidance implies a rebound in revenue and Adjusted EBITDA growth.

auto_awesomeAnalysis

AdaptHealth Corp. reported a challenging 2025, marked by a significant net loss and a decline in Adjusted EBITDA, primarily driven by a substantial non-cash goodwill impairment charge. Despite these setbacks, the company demonstrated strong cash flow from operations and made significant progress in debt reduction. The forward-looking 2026 guidance, projecting growth in both net revenue and Adjusted EBITDA, suggests management's confidence in a turnaround, likely driven by strategic investments and a new key capitated contract. Investors will likely weigh the disappointing 2025 results against the optimistic outlook for 2026 and the company's efforts to strengthen its balance sheet.